GlaxoSmithKline PLC (UK) Today
| GSK Stock | 1,342 32.50 2.48% |
Performance0 of 100
| Odds Of DistressLess than 21
|
GlaxoSmithKline PLC is trading at 1342.00 as of the 25th of November 2024, a 2.48 percent increase since the beginning of the trading day. The stock's lowest day price was 1319.5. GlaxoSmithKline PLC has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for GlaxoSmithKline PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
GlaxoSmithKline PLC is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 4.08 B outstanding shares. More on GlaxoSmithKline PLC
Moving together with GlaxoSmithKline Stock
Moving against GlaxoSmithKline Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
GlaxoSmithKline Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. GlaxoSmithKline PLC's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding GlaxoSmithKline PLC or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, GlaxoSmithKline PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GlaxoSmithKline PLC's managers, analysts, and investors.
Environment Score | Governance Score | Social Score |
| President Development | CA BSc | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
| Excise Tax Activities | Animal TestingCatholic | ||||
GlaxoSmithKline PLC's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to GlaxoSmithKline PLC's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsGlaxoSmithKline PLC can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GlaxoSmithKline PLC's financial leverage. It provides some insight into what part of GlaxoSmithKline PLC's total assets is financed by creditors.
| |||||
GlaxoSmithKline PLC (GSK) is traded on London Exchange in UK and employs 70,212 people. GlaxoSmithKline PLC is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 54.76 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GlaxoSmithKline PLC's market, we take the total number of its shares issued and multiply it by GlaxoSmithKline PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. GlaxoSmithKline PLC operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 4.08 B outstanding shares.
GlaxoSmithKline PLC generates positive cash flow from operations, but has no cash available
Check GlaxoSmithKline PLC Probability Of Bankruptcy
Ownership AllocationGlaxoSmithKline PLC has a total of 4.08 Billion outstanding shares. 30% of GlaxoSmithKline PLC outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check GlaxoSmithKline Ownership Details
GlaxoSmithKline PLC Risk Profiles
Although GlaxoSmithKline PLC's alpha and beta are two of the key measurements used to evaluate GlaxoSmithKline PLC's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.9397 | |||
| Standard Deviation | 1.25 | |||
| Variance | 1.57 | |||
| Risk Adjusted Performance | (0.14) |
GlaxoSmithKline Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in GlaxoSmithKline PLC without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
GlaxoSmithKline PLC Corporate Management
Elected by the shareholders, the GlaxoSmithKline PLC's board of directors comprises two types of representatives: GlaxoSmithKline PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline PLC's management team and ensure that shareholders' interests are well served. GlaxoSmithKline PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Luke Miels | Chief Officer | Profile | |
| Emma Walmsley | CEO Director | Profile | |
| Sally Jackson | Senior Office | Profile | |
| James Ford | Senior Compliance | Profile |
Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline PLC financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline PLC security.